ARID1A Alterations Function as a Biomarker for Longer Progression-Free Survival After Anti-Pd-1/Pd-L1 Immunotherapy

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1136/jitc-2019-000438
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

The Role of PD-1/PD-L1 Axis in Treg Development and Function: Implications for Cancer Immunotherapy

OncoTargets and Therapy
OncologyPharmacology
2019English

Long-Term Survival in Patients Responding to Anti-Pd-1/Pd-L1 Therapy and Disease Outcome Upon Treatment Discontinuation

Clinical Cancer Research
Cancer ResearchOncology
2019English

Endothelial PD-L1 Expression as a Biomarker for Acute Rejection in Heart Transplantation

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

CD84 Regulates PD-1/PD-L1 Expression and Function in Chronic Lymphocytic Leukemia

Journal of Clinical Investigation
Medicine
2018English

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2020English

Macrophage PD-L1 Strikes Back: PD-1/PD-L1 Interaction Drives Macrophages Toward Regulatory Subsets

Advances in Bioscience and Biotechnology
2013English

823 Biomarker Approaches for Anti-Pd-1 in Melanoma: A Meta-Analysis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

PD-L1 Expression Predicts Longer Disease Free Survival in High Risk Head and Neck Cutaneous Squamous Cell Carcinoma

Pathology
Forensic MedicinePathology
2017English

PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer

Medicinski podmladak
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy